Chungcheongbuk-do, South Korea

Su Min Park

USPTO Granted Patents = 3 

Average Co-Inventor Count = 13.0

ph-index = 1


Company Filing History:


Years Active: 2022-2025

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of Su Min Park

Introduction

Su Min Park is a notable inventor based in Chungcheongbuk-do, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on aminopyridine derivative compounds. With a total of 3 patents to his name, Park continues to push the boundaries of scientific research and development.

Latest Patents

Among his latest patents is the invention of a novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide. This invention includes a crystalline form and a process for preparing the same. The mesylate salt demonstrates excellent stability, solubility, and bioavailability, making it effective both alone and in combination with other drugs. Additionally, it boasts high purity, which is crucial for pharmaceutical applications.

Career Highlights

Su Min Park is currently employed at Yuhan Corporation, a leading pharmaceutical company in South Korea. His work at Yuhan Corporation has allowed him to focus on developing innovative solutions that address various medical needs. His expertise in chemistry and pharmacology has been instrumental in advancing the company's research initiatives.

Collaborations

Throughout his career, Park has collaborated with talented individuals such as Sang Ho Oh and Jong Gyun Kim. These collaborations have fostered a creative environment that encourages the exchange of ideas and enhances the quality of their research.

Conclusion

Su Min Park's contributions to the field of pharmaceuticals through his innovative patents highlight his dedication to improving drug efficacy and safety. His work continues to inspire future advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…